• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

    0.0549 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Adaptimmune Therapeutics plc - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
    Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will... 
    Via Newsfile
    News headline image
    This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For November 13, 2024 ↗
     
    Via Benzinga
    News headline image
    Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics ↗
     
    Via Benzinga
    News headline image
    Adaptimmune Reports Q1 Financial Results and Provides Business Update
    TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in... 
    Via Newsfile
    News headline image
    A Look Ahead: Adaptimmune Therapeutics's Earnings Forecast ↗
     
    Via Benzinga
    News headline image
    Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
    Via Newsfile
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For May 13, 2025 ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Tuesday's after hours session: top gainers and losers ↗
    Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
    Via Chartmill
    News headline image
    What Analysts Are Saying About Adaptimmune Therapeutics Stock ↗
     
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
    Via Chartmill
    News headline image
    Here are the top movers in Thursday's session. ↗
    Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
    Via Chartmill
    News headline image
    Top movers in Thursday's session ↗
    Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Which stocks are gapping on Thursday? ↗
    The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
    Via Chartmill
    News headline image
    Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    Adaptimmune Provides Q4 and Full Year 2024 Business Update
    TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and... 
    Via Newsfile
    News headline image
    Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
    Via Newsfile
    News headline image
    Earnings Scheduled For March 20, 2025 ↗
     
    Via Benzinga
    News headline image
    Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working... 
    Via Newsfile
    News headline image
    Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
    The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other... 
    Via Newsfile
    News headline image
    Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
    Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31,... 
    Via Newsfile
    Topics Initial Public Offering
    News headline image
    First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company... 
    Via Newsfile
    News headline image
    Adaptimmune Reports Q3 2024 Financial and Business Updates
    Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed... 
    Via Newsfile
    News headline image
    Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
    42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses... 
    Via Newsfile
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.